EC<sub>50</sub> images, a novel endpoint from PET target occupancy studies, reveal spatial variation in apparent drug affinity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 34636937.
- Also identified by DOI 10.1007/s00259-021-05561-3.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We recently introduced voxel-level images of drug occupancy from PET via our "Lassen plot filter." Occupancy images revealed clear dependence of <sup>11</sup>C-flumazenil displacement on dose of GABAa inhibitor, CVL-865, but with different scales in different brain regions. We hypothesized that regions requiring higher drug concentrations to achieve desired occupancy would have higher EC<sub>50</sub> values. We introduce an "EC<sub>50</sub> image" from human data to evaluate this hypothesis. Five healthy subjects were scanned with the nonselective GABAa tracer, <sup>11</sup>C-flumazenil, before and (twice) after administration of CVL-865. We created ten occupancy images and applied an E<sub>max</sub> model locally to create one EC<sub>50</sub> image. We also performed simulations to confirm our observations of regional variation in EC<sub>50</sub> and to identify the main source of variability in EC<sub>50</sub>. As expected, the EC<sub>50</sub> image revealed spatial variation in apparent drug affinity. High EC<sub>50</sub> was found in areas of low occupancy for a given drug dose. Simulations demonstrated that sampling from an inadequate range of plasma drug concentrations could impair precision. Our results argue for (a) confidence in the ability of the EC<sub>50</sub> images to identify regional differences and (b) a need to tailor the range of drug doses in an occupancy study to regularize the precision of the EC<sub>50</sub> throughout the brain. The EC<sub>50</sub> image could add value to early-phase drug development by identifying regional variation in affinity that might impact therapy or safety and by guiding dose selection for later-phase trials.
Medical subject headings
- Flumazenil
- Positron-Emission Tomography